Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
TCR-engineered T-cells directed against Ropporin-1 consti... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models
0
Authors
Dian Kortleve
21 more
Dian Kortleve
•
Chen-Yi Liao
19 more
•
Reno Debets
Published
January 11, 2024
Paper
Conversation
0
Reviews
0
Bounties
0
Loading PDF viewer…
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Immunology
T-Cell Receptor
Triple-Negative Breast Cancer
Show all topics
DOI
10.1101/2024.01.10.574978
License
CC-BY-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Immunology
T-Cell Receptor
Triple-Negative Breast Cancer
Show all topics
DOI
10.1101/2024.01.10.574978
License
CC-BY-ND
Other Formats
PDF
